The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...

Tenpoint Therapeutics, Ltd., a global, commercial-stage ophthalmic pharmaceutical company focused on developing ...

(RTTNews) - Viatris Inc. (VTRS), a healthcare company, on Wednesday said the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for phentolamine ...

Yuvezzi, an eye drop for the treatment of presbyopia, is now available in the U.S.

Pharmacotherapy is the newest modality of presbyopia management, with the first agent (pilocarpine) gaining FDA approval for presbyopia in 2021. It offers a local, non-invasive, and reversible ...

(RTTNews) - LENZ Therapeutics, Inc. (LENZ), a pharmaceutical company that recently secured FDA approval for its aceclidine ophthalmic solution VIZZ for presbyopia, has reported preliminary Q4 ...

LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater ...

PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ...

Vuity contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity. The Food and Drug Administration (FDA) has approved the supplemental New Drug ...

BRIMOCHOL™ PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well-tolerated with no ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

"Presbyopia Pipeline"Major companies actively shaping the presbyopia treatment landscape include Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, ...